Evidence map›Paper›PMID 36900371›Full record

ArticleCancers2023

Treatment Patterns, Testing Practices, and Outcomes in Patients with

Adam Pluzanski, Maciej Bryl, Izabela Chmielewska, Grzegorz Czyzewicz, Joanna Luboch-Kowal, Anna Wrona, Agnieszka Samborska, Maciej Krzakowski

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. The Predictive Value ofCurrent medical imaging · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adam PluzanskiLung Cancer and Chest Tumors Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0002-3710-6445
Maciej BrylDepartment of Clinical Oncology with the Subdepartment of Diurnal Chemotherapy, E. J. Zeyland Wielkopolska Center of Pulmonology and Thoracic Surgery, 60-569 Poznan, Poland.ORCID 0000-0001-6873-5861
Izabela ChmielewskaDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.ORCID 0000-0002-0948-9071
Grzegorz CzyzewiczDepartment of Oncology, The John Paul II Specialist Hospital, 31-202 Cracow, Poland.
Joanna Luboch-KowalDepartment of Oncology, Lower Silesian Oncology Center, Home Hospice, Wroclaw Medical University, 53-413 Wroclaw, Poland.
Anna WronaDepartment of Oncology and Radiotherapy, Medical University of Gdansk, 80-210 Gdansk, Poland.
Agnieszka SamborskaAstraZeneca Pharma Poland Sp.zo.o., 02-676 Warsaw, Poland.
Maciej KrzakowskiLung Cancer and Chest Tumors Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.

Funding

AstraZeneca (Poland) NCT04031898
6 · The paper itself

Abstract

Non-small-cell lung cancer (NSCLC) represents 85% of new cases of lung cancer. Over the past two decades, treatment of patients with NSCLC has evolved from the empiric use of chemotherapy to more advanced targeted therapy dedicated to patients with an epidermal growth factor receptor (

Indexed as

brain metastasesEGFR mutationnon-small-cell lung cancerreal-world datatyrosine kinase inhibitors

Identifiers

PMID36900371
PMCPMC10000701

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read79
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.